<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="241">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 24, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342897</url>
  </required_header>
  <id_info>
    <org_study_id>17824</org_study_id>
    <secondary_id>I7W-MC-UDAA</secondary_id>
    <nct_id>NCT04342897</nct_id>
  </id_info>
  <brief_title>A Study of LY3127804 in Participants With COVID-19</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants
      who are hospitalized with pneumonia and presumed or confirmed COVID-19. The study may last up
      to 9 weeks and include daily visits up to day 28, and follow-up visits by phone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">July 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Ventilator Free Days</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Number of days on which a participant breathes without assistance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Each Severity Rating on the National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Assessment</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>The scale is an assessment of clinical status. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation (SpOâ‚‚)</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Oxygen Saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Flow Rate</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Oxygen Flow Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Post First Dose Up to Day 28</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospitalization</measure>
    <time_frame>Baseline up to at Least Week 6</time_frame>
    <description>Days of Hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with any Serious Adverse Event (SAE)</measure>
    <time_frame>Day 1 up to Day 60</time_frame>
    <description>Number of Participants with any Serious Adverse Event (SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with any Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>Day 1 up to Day 60</time_frame>
    <description>Number of Participants with any Treatment Emergent Adverse Event (TEAE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>LY3127804</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3127804 administered intravenously (IV), with standard of care treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV, with standard of care treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3127804</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3127804</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are hospitalized with pneumonia, and presumed or confirmed COVID-19

          -  Are able and willing to give signed informed consent (legally authorized
             representative can provide informed consent if needed)

        Exclusion Criteria:

          -  Female participants must not be pregnant and/or lactating

          -  Have Acute Respiratory Distress Syndrome (ARDS) or will require immediate intermittent
             mandatory ventilation (IMV), or are ineligible for IMV

          -  Have any concurrent serious medical condition (for example active malignancies on
             chemotherapy, post organ transplant, dialysis) or concomitant medication that would
             preclude participation in the study

          -  Are moribund irrespective of the provision of treatments

          -  Have a known history or show evidence of human immunodeficiency virus (HIV) and/or
             hepatitis

          -  Receiving full-dose anticoagulation therapy with warfarin or other anticoagulants

          -  Have recently undergone major surgery or central venous access device placement

          -  Have a significant bleeding disorder or vasculitis

          -  Have experienced a thromboembolic event

          -  Have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac
             arrhythmia

          -  Have a serious, nonhealing wound, peptic ulcer, or bone fracture

          -  Have liver cirrhosis

          -  Have a known sensitivity to monoclonal antibodies (mAbs) or other therapeutic proteins

          -  Have a history of hypertensive crisis or hypertensive encephalopathy or current,
             poorly controlled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-265-4559 or 1-317-615-4559) Mon - Fri 9AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Franciscan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-528-7060</phone>
    </contact>
    <investigator>
      <last_name>Imad J Shawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/covid-19--coronavirus-/UDAA#?postal=</url>
    <description>A Study of LY3127804 in Participants With COVID-19</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corona Virus Disease 19 (COVID-19)</keyword>
  <keyword>2019 Novel Coronavirus (2019 n-COV)</keyword>
  <keyword>Severe Acute Respiratory Syndrome (SARS)</keyword>
  <keyword>Pulmonary Disease</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting</ipd_time_frame>
    <ipd_access_criteria>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

